First Tracks Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from First Tracks Biotherapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-65.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 78% of Healthcare companies in United States.
Cash Cushion Ratio
+24%Cash, after subtracting all debt, equals 24% of its market value (net cash).
Higher than 66% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
First Tracks Biotherapeutics, Inc. made a loss over the last year. First Tracks Biotherapeutics, Inc. owes $0.08 for every $1 it owns. First Tracks Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2024.
P/E ratio
LossFirst Tracks Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
9.32The share price is 9.32 times First Tracks Biotherapeutics, Inc.'s book value per share, higher than 85% of Healthcare companies in United States.
Market cap
$1.6 BThe total market value of all of First Tracks Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 70% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$169 MWhat First Tracks Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.72Net worth divided by the number of shares. The share price of $44.05 is 9.3 times this, which is the P/B above.
Owes vs Owns
0.08×First Tracks Biotherapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneFirst Tracks Biotherapeutics, Inc. does not currently pay a dividend.
Profit growth
LossFirst Tracks Biotherapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashFirst Tracks Biotherapeutics, Inc. held $369 M more cash than debt (net cash) at Dec 2024.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For First Tracks Biotherapeutics, Inc.: $1.6 B ÷ $169 M (30 Jun 2026) = 9.3.
How much does First Tracks Biotherapeutics, Inc. owe compared with what it owns?
First Tracks Biotherapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does First Tracks Biotherapeutics, Inc. pay a dividend?
No. First Tracks Biotherapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.